

# Optimisation of a Novel Bio-Substrate as a Treatment for Atrophic Age-Related Macular Degeneration

1 **Rachel McCormick<sup>1</sup>, Ian Pearce<sup>2</sup>, Stephen Kaye<sup>1,2</sup>, Atikah Haneef<sup>1\*</sup>**

2 <sup>1</sup>Institute of Ageing and Chronic Disease, Department of Eye and Vision Science, The University of  
3 Liverpool, Liverpool, United Kingdom

4 <sup>2</sup>St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom

5 **\* Correspondence:**

6 Dr. Atikah Haneef

7 atikahh@liverpool.ac.uk

8 **Keywords: AMD<sup>1</sup>, electrospinning<sup>2</sup>, electrospaying<sup>3</sup>, nanoparticles<sup>4</sup>, sustained releases<sup>5</sup>,**  
9 **composite<sup>6</sup>, substrate<sup>7</sup>, coaxial<sup>8</sup>.**

10 **Word count: 4013**

11 **Number of figures/tables: 14**

12 **British English used throughout manuscript**

13 **Abstract**

14 Atrophic age-related macular degeneration (AMD) is the most common form of AMD accounting for  
15 90% of patients. During atrophic AMD the waste/exchange pathway between the blood supply  
16 (choroid) and the retinal pigment epithelium (RPE) is compromised. This results in atrophy and death  
17 of the RPE cells and subsequently the photoreceptors leading to central blindness. Although the  
18 mechanisms behind AMD are unknown, the growth of fatty deposits known as drusen, have been  
19 shown to play a role in the disease. There is currently no treatment or cure for atrophic AMD. Much  
20 research focuses on developing a synthetic substrate in order to transplant healthy cells to the native  
21 Bruch's membrane (BM), however, the diseased native BM and related structures still leave the  
22 potential for transplanted cells to succumb to disease. In this work we electrospun poly(ethylene  
23 terephthalate) (PET) to fabricate a nanofibrous cytocompatible synthetic BM. The apical surface of  
24 the membrane was cultured with ARPE-19 cells and the basal surface was decorated with poly(lactic  
25 acid-co-glycolic acid) (PLGA) or poly(glycolic acid) (PGA) degradable nanoparticles by  
26 electrospaying. The membrane exhibited hydrophilicity, high tensile strength and structurally  
27 resembled the native BM. ARPE-19 cells were able to form a monolayer on the surface of the  
28 membrane and no cell invasion into the membrane was seen. The presence of both PLGA and PGA  
29 nanoparticles increased ARPE-19 cell metabolism but had no effect on cell viability. There was a  
30 decrease in pH of ARPE-19 cell culture media 7 days following culturing with the PLGA nanoparticles  
31 but this change was eliminated by 2 weeks; PGA nanoparticles had no effect on cell culture media pH.  
32 The fluorescent dye FITC was encapsulated into nanoparticles and showed sustained release from  
33 PLGA nanoparticles for two weeks and PGA nanoparticles for 1 day. Future work will focus on  
34 encapsulating biologically active moieties to target drusen. This would allow this novel bioactive  
35 substrate to be a potential treatment for atrophic AMD that would function two-fold: deliver the

36 required monolayer of healthy RPE cells to the macula on a synthetic BM and remove diseased  
37 structures within the retina, restoring the waste/exchange pathway and preventing vision loss.

## 38 **Introduction**

39 Age-related macular degeneration (AMD) is a progressive disease of the retina that is the leading form  
40 of blindness in developed countries. It is a form of central blindness that mainly affects people over  
41 the age of 50 years. Although the pathology of AMD is currently unknown, age is considered to be the  
42 main contributing factor to the manifestation of this disease (Nowak 2006, Curcio and Johnson 2013).  
43 There are two forms of AMD; neovascular and atrophic. Neovascular (or wet) AMD makes up 10%  
44 of all reported cases where new abnormal leaking blood vessels break through a layer underlying the  
45 retina called the Bruch's membrane (BM) leading to a loss of central vision. There has been significant  
46 developments and improvements in the management of neovascular AMD such as intravitreal  
47 injections of anti-vascular endothelial growth factor (anti-VEGF) to prevent any further growth of  
48 abnormal blood vessels. Atrophic (or dry) AMD, however, makes up 90% of all cases. It is associated  
49 with a slowly progressive form of sight loss where fatty deposits known as drusen, form on BM leading  
50 to alterations and atrophy of the RPE. The RPE is the main source of nutrient/waste exchange; if the  
51 RPE fails it leads on to photoreceptor death, ultimately leading to central blindness. Although several  
52 risk factors for atrophic AMD are known, there are no available treatments other than supportive optical  
53 aids.

54 Much research focuses on developing a synthetic cell transplantation substrate in order to transplant  
55 healthy RPE cells onto BM as a treatment for atrophic AMD (Lu, Zhu et al. 2012, Liu, Yu et al. 2014,  
56 Surrao, Greferath et al. 2017, da Cruz, Fynes et al. 2018, Tan, Sing et al. 2019). The underlying native  
57 diseased BM and related structures remain, however, which leaves the potential for healthy  
58 transplanted cells to eventually succumb to disease (White and Olabisi 2017).

59 Recent research has explored using an anti-inflammatory, antiatherogenic peptide L-4F to reduce the  
60 accumulation of fatty deposits on BM of *Macaca fascicularis*, via intravitreal injection of L-4F  
61 (Rudolf, Curcio et al. 2019). Those eyes injected with L-4F were found to have had clearance of the  
62 fatty deposits along the BM without harming surrounding ultrastructure in the retina. This is  
63 particularly interesting, as they described the drug to be well tolerated at even the highest dose, with  
64 the only adverse events attributed to the physical process of the injection. Interestingly they found that  
65 the effect of the drug was seen bilaterally, even though only one eye was injected with the drug while  
66 the other was meant to serve as a control (Rudolf, Curcio et al. 2019).

67 There is, therefore, scope to provide a two-pronged approach for a potential treatment for atrophic  
68 AMD. That is, a persistent bioactive substrate that would function two-fold; provide a permanent  
69 basement layer for transplantation of healthy RPE cells to the area required, while removing diseased  
70 structures (drusen) on the BM and fatty deposits (lipofuscin) within the retina (Curcio and Johnson  
71 2012), using moieties such as L-4F. This would replenish the native BM nutrient/waste exchange  
72 pathway, preventing the progressive loss of photoreceptors, through a more controlled and localized  
73 effect. Our aim is to develop a bioactive persistent cell transplant substrate for the treatment for  
74 atrophic AMD. This article describes the development of a composite membrane for this two-pronged  
75 approach.

76

77

## 78 **Material and methods**

### 79 **Electrospinning of PET scaffold**

80 Poly(ethylene terephthalate) PET pellets (04301, Polysciences Inc) were dissolved in neat 1,1,1-3,3,3-  
81 hexafluoroisopropanol (HFIP) (Apollo Scientific Ltd.) at a concentration of 17.5% (w/v). The fibres  
82 were collected for 15 minutes under laboratory conditions on a grounded plate covered with aluminium  
83 foil at a working distance of 15cm, flow rate of 2ml/h and a voltage of 25kV.

### 85 **Electrospraying of PLGA and PGA nanoparticles**

87 Poly(lactic acid-co-glycolic acid) 50/50 (PLGA) (26269, Polysciences Inc) was dissolved in neat  
88 chloroform (Merck) at a concentration of 2% (w/v). Poly(glycolic acid) (PGA) (06525, Polysciences  
89 Inc) was dissolved in neat HFIP at a concentration of 1% (w/v) and left to stir overnight at room  
90 temperature. For nanoparticle encapsulation, 2mM of FITC was added to the solvents at the same time  
91 as the polymers. The homogeneous polymer solution was introduced into a 10mL plastic syringe and  
92 a blunt-tip needle attached. Any air bubbles were removed and the filled syringe was fixed in a  
93 mechanical syringe pump. All work was carried out at ambient conditions in a fume-hood.  
94 Nanoparticles were sprayed into a glass dish filled with 0.1% (v/v) isopropanol (Merck) in dH<sub>2</sub>O placed  
95 on a magnetic stirrer, connected to a grounding plate and left to spray for 1h. Working parameters for  
96 PGA nanoparticles were 25kV, 25cm working distance, 2ml/hr flow rate; and for PLGA nanoparticles;  
97 11kV, 13cm working distance, 0.5ml flow rate.

### 98 **Fibre and nanoparticle diameter measurements**

99 The diameter of 50 fibres and nanoparticles from 3 different images of the electrospun fibres and  
100 electrospayed nanoparticles were measured using ImageJ. (n = 3).

### 101 **Preparation of fibres and nanoparticles for SEM**

102  
103 Electrospun membrane or 10µl of electrospayed nanoparticles suspended in solution was placed on a  
104 carbon tab (TAAB) mounted on an aluminium stub (TAAB). The nanoparticles were surrounded by a  
105 layer of silver dag (Merck) and were left overnight in a desiccator for the solution to evaporate.  
106 Membrane or nanoparticles were gold sputter coated (Quorum) and imaged using SEM (Quanta  
107 FEG250 ESEM) with EHT of 5kV. (n = 3).

### 109 **Contact angle measurements**

110 Electrospun membrane was cut into 3cm x 1cm rectangles. Samples were either untreated, UV treated  
111 (1 hour), placed in ethanol, or placed in cell culture medium and left to dry before being measured for  
112 changes in wettability using DSA 100 (Kruss-Scientific). (n = 6).

### 113 **Tensile testing**

114 Quantitative tensile testing of the electrospun membrane was undertaken using UniVert tensile tester  
115 (CellScale) equipped with a 10N load cell at a displacement rate of 12mm/minute. The membranes  
116 were cut into dog-bone shaped strips 2cm in length by 0.5cm in width and tested until failure or until  
117 the tensile tester had reached maximum distance (n = 16). Membrane thickness was measured using a

118 digital micrometer (HITEC, 190-00, Farnell). For wet samples (n = 7), samples were soaked in dH<sub>2</sub>O  
119 before mounting into the tensile tester.

120

## 121 **FTIR**

122

123 Electrospun membranes were cut into 3cm x 1cm rectangles. Samples were either untreated, UV treated  
124 (1 hour), placed in ethanol, or placed in cell culture medium and left to dry before being measured  
125 using Vertex 70 Fourier Transform Infrared Spectrometer (Vertex). (n = 6).

126

## 127 **Cell culture**

128

129 Electrospun membrane was cut into 1.5cm<sup>2</sup> squares and placed in Scaffdex (Merck). ARPE-19 cells  
130 (ATCC-LGC, CRL-2302) were seeded at a density of 50,000 cells/sample and incubated at 37°C, 5%  
131 CO<sub>2</sub>, 98–99% humidity and grown for 1 month or 3 months. Media consisted of DMEM:F12 (Merck)  
132 containing 10% FCS (Thermofisher Scientific), 2.5mg/L amphotericin B (Merck) and penicillin-  
133 streptomycin (Merck). Media was changed every three days. Controls were glass coverslips (Agar).

134

135 For long-term culture, the membrane was fabricated as aforementioned and then mounted onto a  
136 grounded water bath as described. Nanoparticles were sprayed onto the membrane using the described  
137 parameters followed by cutting and mounting into Scaffdex with the nanoparticle decorated side  
138 orientated to be the basal side. Cells were seeded onto the apical side and cultured as mentioned above.

## 139 **Histology**

140 Cell cultured membranes were fixed in 10% NBF for 15 minutes and processed for histological staining  
141 with Leica TP1020. Following processing, tissues were embedded for sectioning in paraffin wax and  
142 stained with H&E using standard protocol. (n = 4).

## 143 **Preparation of cells for SEM**

144 Cells were fixed in 1.5% Glutaraldehyde (Fluka) for 30 minutes at 4°C and dehydrated with graded  
145 ethanol; 2 x 3 min 50%, 2 x 3 min 70%, 2 x 3 min at 90%, 2 x 5 min at 100%. Hexamethyldisilane  
146 (HMDS, Merck) was added for 2 x 5 mins and left overnight to evaporate. Samples were mounted on  
147 a carbon tab on an aluminium stub, gold sputter coated (Quorum) and imaged using SEM (Quanta  
148 FEG250 ESEM) with EHT of 5kV. (n = 3).

## 149 **Immunofluorescence staining**

150 Cell cultured membranes were harvested after 1 or 3 months of culture, washed with DPBS and fixed  
151 in 10% NBF for 15 minutes. Cells were permeabilised with 1% Triton-X for 10 minutes, blocked with  
152 10% goat serum for 30 minutes and incubated with primary antibodies (table 1) overnight at 4°C. The  
153 following day, cells were incubated with the appropriate secondary antibody for 1 hour, followed by  
154 DAPI staining, and membrane placed on glass slides and mounted to coverslips with Vectorshield  
155 (Vectorlabs). Slides were viewed using the Zeiss ImagerM1 microscope. (n = 3).

## 156 **Resazurin Assay**

157

158 Resazurin solution (5mg resazurin salt in 40mL Dulbecco's phosphate buffered saline) (DPBS) (PAA  
159 laboratories), was added to each sample (100µl/ml) and returned to the incubator for 4 hours. A 100µl  
160 aliquot of media was taken from each sample and transferred into a black bottomed 96-well plate.

161 Fluorescence was measured at 530–510nm excitation and 590nm emission using a fluorescence reader  
162 (FLUOstar OPTIMA, BMG LABTECH). (n = 4).

163

### 164 **Barrier assay**

165 Scaffoldex mounted membranes, with or without cells, were placed in 12 well plates with DPBS on the  
166 basal side of the membranes. On the apical side of the membranes, 1mM FITC (Merck) in DPBS was  
167 added. Every 10 minutes, 100µl of DPBS was taken from the basal side of the membranes and  
168 measured using the fluorescence reader (FLUOstar OPTIMA, BMG LABTECH). (n = 4).

169

### 170 **Live/dead assay**

171

172 Cell cultured membranes were washed in DPBS and following manufacturer's instructions (molecular  
173 probes) incubated with calcein AM and ethidium homodimer-1 for 30 minutes. The material was  
174 placed on glass slides and mounted to coverslips with Vectorshield (Vectorlabs). Slides were viewed  
175 using the Zeiss ImagerM1 microscope. (n = 3).

176

### 177 **pH measurements**

178

179 Three pH measurements were taken from each well using a digital pH meter (Mettler-Toledo). (n = 6).

180

### 181 **Measurement of nanoparticle degradation**

182

183 Following electrospraying, 10ml of collected nanoparticles in 0.1% (v/v) isopropanol was kept at 37°C.  
184 An aliquot (1ml) of solution was then collected at each time point and kept at -20°C until the final time  
185 point. For collection from cell cultures 1ml of media was collected at each time point and media  
186 changed. A 100µl aliquot was taken from each sample and transferred into a black bottomed 96-well  
187 plate. Fluorescence was measured at 530–510nm excitation and 590nm emission using a fluorescence  
188 reader (FLUOstar OPTIMA, BMG LABTECH). (n = 4).

189

### 190 **Statistical analysis**

191

192 Data are presented as mean (+/- standard error) with n values noted within the text. Analysis was  
193 undertaken using GraphPad Prism software using t-tests or one-way ANOVA followed by the  
194 appropriate post-test noted within the text. Significance was  $p < 0.05$ .

195

## 196 **Results & Discussion**

### 197 **Characterisation of electrospun PET: Morphology, FTIR, hydrophilicity, mechanical** 198 **properties, barrier assay, and cell culture**

199 Scaffolds were characterized for adequate mechanical properties to undergo surgical handling and the  
200 ultrastructure was characterized to match fibre morphology to mimic the native BM (Yamamoto and  
201 Yamashita 1989, Del Priore, Tezel et al. 2006). Surface chemistry was analyzed for presence of  
202 functional groups following surface treatment and hydrophilic properties measured using water contact  
203 angle (WCA). Barrier properties were analyzed with and without a monolayer of cells to ascertain any  
204 changes with cell culture.



205 Nanofibrous non-degradable PET fibres were produced in a collectable membrane form. SEM  
206 micrographs showed the membranes exhibited a randomly orientated fibrous mesh (figure 1A); an  
207 open network of interconnected voids with average fibre diameter of 387nm (+/- 147.8) (figure 1B).  
208 The membrane was able to undergo folding, rolling, and twisting without being destroyed; depicting  
209 the ease with which it could be handled and exhibiting adequate mechanical properties (figure 1C-D).  
210 The handling properties were in agreement with previously published work, even though the  
211 concentration of the polymer solution used was lower than previous work (Haneef and Downes 2015).  
212 Morphologically this electrospun membrane mimics native BM (Yamamoto and Yamashita 1989).

213 The membrane gave an interesting stress vs. strain profile following tensile testing; exhibiting an elastic  
214 region (original form is retained following release of load) and a plastic region (membrane deforms  
215 indefinitely) before attaining failure exhibiting the ultimate tensile strength (UTS) (figure 2A-B). 16%  
216 of membranes tested did not break (figure S1, supplementary data). Soaking the membranes in dH<sub>2</sub>O  
217 did not significantly change the Young's modulus (YM) of the elastic region (figure 2C), however, the  
218 YM of the plastic region significantly increased from 5.5MPa (+/-0.8) to 13.8MPa (+/-3.5) and the  
219 UTS significantly increased from an average of 11.23MPa (+/-1.5) to 20.29MPa (+/-5.3) (figure 2D-  
220 E). Wetting the membrane introduced hydrogen bonding between the fibres thereby increasing the  
221 YM of the plastic region and the UTS, while in the dry form the fibres did not have the water to provide  
222 the added interactions (Chen, Cheng et al. 2018, Kurokawa, Kimura et al. 2018).

223 Treatment of the membrane with cell culture media significantly increased hydrophilicity compared to  
224 all other treatment methods, whereas ethanol treatment resulted in an increase in the hydrophilicity  
225 compared only to UV treatment. WCA of control membranes averaged at 132.6° which decreased to  
226 85.8° and 118.4° following treatment with media and ethanol respectively (figure 3A-B, table S1,  
227 supplementary data). FTIR spectra exhibit the characteristic carbonyl peak in PET membrane typical  
228 of the ester bond group within the polymer structure, denoted by the strong peak at ~1700cm<sup>-1</sup> for C=O.  
229 No changes were detected for any of the membranes except the cell culture media treated membrane.  
230 A peak at ~3400cm<sup>-1</sup> denoting the presence of O-H group was detected, suggesting that the surface of  
231 the membrane underwent a degree of functional group opening to form -COOH free groups that could  
232 be attributed to protein interaction or hydrolysis of the surface of the polymer (figure 4A-D) (Haneef  
233 and Downes 2015, Kawai, Kawabata et al. 2019).

234 SEM and phalloidin staining showed cells were able to form a monolayer when cultured on the  
235 membrane up to 3 months, with microvilli that are phenotypical of RPE cells (Thomson, Treharne et  
236 al. 2011) presenting after 1-month's culture (figure 5A-F). Although the auto-fluorescence of the  
237 membrane fibres made it challenging to see clearly, cells plated on the membrane stained positively  
238 for the characteristic proteins of RPE cells (Liao, Yu et al. 2010, Brandl, Zimmermann et al. 2014) in  
239 comparison with positive controls (figure 6). This is particularly noticeable with BEST1 (bestrophin-  
240 1), a Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel (CaCC) specifically expressed in the retinal pigment epithelium (RPE)  
241 of the eye (Kittredge, Ji et al. 2018), USO1 (General vesicular transport factor p115) and GULP (PTB  
242 domain-containing engulfment adaptor protein 1), an adaptor protein involved in phagocytosis (Park,  
243 Kang et al. 2008), an important function of RPE with involvement in the phagocytosis of photoreceptor  
244 outer segments (Sparrow, Hicks et al. 2010).

245 H&E stained sections showed the lack of cell invasion in the bulk structure of the membrane, which  
246 was the desired characteristic at both 1 week and 3 months' culture (figure 7A-B) This was further  
247 confirmed with SEM imaging showing the absence of any cells on the basal side of the membrane  
248 following cell culture on the apical side (figure 7C).

249 Resazurin assays showed the metabolism of the cells cultured on the membrane was significantly lower  
250 compared to positive control in the initial first week of culture, thereafter, the metabolism was not  
251 significantly different to the positive control (figure 8). This may have been due to cells not adhering  
252 as quickly due to the porosity of the membrane, as this difference in metabolism was overcome by 2  
253 weeks. These data are in contrast to previous studies by our group that have shown RPE cells had  
254 increased metabolism when plated on an electrospun PET membrane (Haneef and Downes 2015),  
255 however, the membrane formed in the previous study was electrospun for 1 hour and had thinner fibres,  
256 giving the membrane a different morphology. Current results show that ARPE-19 cells were able to  
257 form a monolayer, express proteins and exhibit microvilli phenotypical to the RPE cells, after long-  
258 term culture on the current electrospun membrane.

259 To determine the permeability of the membrane a barrier assay was carried out on acellular membranes  
260 and on membranes cultured with ARPE-19 cells for 1 month, as this was when a monolayer had  
261 formed. The barrier assay on acellular membranes showed FITC was able to passively diffuse through  
262 the membrane in a time dependent manner, taking 80 minutes for maximum signal to be detected  
263 (figure 9A). Cell cultured membranes showed the transport of FITC had increased with fluorescence  
264 plateauing within the first 10 minutes of culture, suggesting the monolayer of cells were actively  
265 transporting the FITC across the membrane and functioning correctly (figure 9B). These data showed  
266 that cells plated on the material did not affect the permeability of the membrane and shows it has the  
267 appropriate properties to act as an artificial BM.

268 Future experiments to confirm the ability of the RPE cells to perform phagocytosis when seeded on  
269 the PET membrane are needed. The presence of the phagocytosis marker MERKT in the ARPE-19  
270 cells cultured on the PET membrane (figure 6) suggested the cells had phagocytic potential.  
271 Furthermore, a study by Cruz et al, have shown the ability of human embryonic RPE cells plated onto  
272 a PET membrane to phagocytose both *in vitro* and following surgical implantation (da Cruz, Fynes et  
273 al. 2018).

## 274 **Nanoparticles**

275 Spherical nanoparticles were successfully fabricated with average nanoparticle diameters at 480nm  
276 (+/- 252) for PLGA and 59nm (+/-49) for PGA (figure 10A-D). Interestingly less variation in particle  
277 size was seen in PGA particles.

278 The nanoparticles did not affect ARPE-19 cell viability or morphology when compared with the  
279 membrane only control (figure 11); cells attached 24hours following seeding and formed a monolayer  
280 by 1 month in the presence of nanoparticles. Resazurin assays showed the presence of nanoparticles  
281 induced a significant increase in cell metabolism compared to the membrane only control up to 2  
282 weeks, which resolved thereafter up to 1 in month in culture (figure 12). The increase in metabolism  
283 may be attributed to the change in pH as the nanoparticles degrade with time; it was found that the pH  
284 of the culture media decreased after 1 week for both PLGA and PGA nanoparticles (figure 13, table  
285 S2, supplementary data). PLGA nanoparticles significantly decreased the pH up to 1 week's  
286 degradation compared to membrane only control. The metabolites of PLGA degradation are lactic acid  
287 and glycolic acid, which contribute to lowering the pH of the surrounding environment. It could also  
288 be attributed to the larger variation in particle size which could be contributing to the significant change  
289 in pH compared to PGA.

290 Although a difference in metabolism of cells and pH of their surrounding environment was observed  
291 when cultured with nanoparticles; morphology and protein expression results suggest that the cells  
292 were not adversely affected by the membrane/nanoparticle composite.

### 293 **Nanoparticle degradation and release profile**

294 Short term degradation studies show that over 72 hours, both PLGA and PGA nanoparticles degraded  
295 releasing FITC into solution (0.1% isopropanol in dH<sub>2</sub>O). PLGA nanoparticles exhibited a continuous  
296 release profile up to 72 hours (figure 14A) compared to the PGA nanoparticles, which exhibited sudden  
297 burst release of the dye after 3 hours, which plateaued after 24 hours (figure 14B).

298 Long term (up to 28 days) degradation studies showed similar results as the short-term studies with  
299 PLGA nanoparticles continuing to sustainably release FITC into solution up to 14 days, decreasing  
300 thereafter (figure 14C). PGA nanoparticles exhibited maximum release after 1 day, but exhibited  
301 considerable decrease in FITC release by day 7 onwards (figure 14D). This can be attributed to the  
302 faster degradation rate of PGA compared to PLGA and also to the higher surface area:volume ratio of  
303 significantly smaller nanoparticles of PGA, which would allow faster release of the dye, due to shorter  
304 diffusion pathway and faster degradation (Sharma, Madan et al. 2016). Observation of the resultant  
305 solution after 28 days degradation would suggest PLGA nanoparticles had released more FITC  
306 compared to PGA nanoparticles (figure S2, supplementary data), however, this could also be attributed  
307 to more FITC encapsulated. Encapsulation efficiency may explain these differences, particularly given  
308 the size difference and inter-variance in size of the produced nanoparticles; however, this was beyond  
309 the scope of this study.

310 Degradation studies on cell cultured PET membranes decorated with FITC encapsulated nanoparticles  
311 on the basal surface, showed PLGA nanoparticles exhibited release of FITC over 28 days. The majority  
312 of the dye release was observed up to 7 days for PLGA nanoparticles with fluorescence decreasing  
313 thereafter; however, PGA nanoparticles exhibited no significant change until after 28 days, with very  
314 little detected fluorescence in comparison to PLGA (figure 14 E-F) and upon comparison to  
315 degradation in isopropanol solution (figure 14 B). This would suggest that nanoparticle degradation  
316 in cell culture media rather than in isopropanol solution offers the nanoparticles a degree of protection  
317 from degradation. The effects of the ions, proteins, lipids and other components of the culture medium  
318 may confer a degree of stability to the nanoparticles (Moore, Rodriguez-Lorenzo et al. 2015) and is an  
319 important factor to consider in final implant design.

### 320 **Conclusion**

321 In this article we have described the development of a composite bioactive membrane that has adequate  
322 mechanical properties, permeability and cytocompatibility. The membrane was able to maintain a  
323 monolayer of RPE cells that exhibited phenotypic microvilli structures on its apical surface while  
324 providing a sustained release of encapsulated moieties from the membrane's basal surface.

325 This composite bioactive membrane exhibits the potential to act as an artificial BM and a potential  
326 treatment for atrophic AMD as a novel bioactive cell transplant substrate; to the authors' knowledge  
327 the first of its kind to be developed as a potential treatment for atrophic AMD.

328 We are now focusing on the optimization and formation of co-axially electrosprayed nanoparticles to  
329 encapsulate biologically active moieties to target drusen, and have already achieved the coaxial  
330 encapsulation of FITC with Nile red as the outer shell via electrospraying (figure S3, supplementary  
331 data). Since electrospraying involves the use of compounds dissolved in solvents, care must be taken



332 when encapsulating biologically active moieties to ensure their activity is not compromised. We have  
333 begun screening solvents for this purpose using enzyme activity agar assays (figure S4, supplementary  
334 data). Further work will then move towards using moieties such as L4-F, to target drusen.

### 335 **Figure Legends**

336 Figure 1. SEM micrograph of 17.5% PET electrospun membrane exhibiting ultrastructure of randomly  
337 orientated fibres (**A**) and corresponding histogram showing distribution of fibre diameter size; average  
338 diameter of 387nm (+/-6.9) (**B**). Photographs of material folded (**C**), rolled (**D**), twisted (**E**) without  
339 breaking denote good handleability of the material (n = 3). Scale shown = 5cm.

340 Figure 2. The membranes gave an interesting stress vs. strain plot, as shown by the representative  
341 profile (**A**) and stretched to deformation (**B**). Young's modulus (YM) for the elastic region (retains  
342 form) are high, with no significant difference between the dry (145.2 MPa (+/-23.46)) and wet (250.2  
343 MPa (+/-73.08) membranes (**C**), whereas the plastic region (deformation) YM significantly increased  
344 from 5.15 MPa (+/- 0.82) (dry) to 13.75 MPa (+/-3.47) (wet) (**D**), and the ultimate tensile strength  
345 (UTS) of the membrane significantly increased from 11.23 MPa (+/-1.5) (dry) to 20.29 MPa (+/-5.3)  
346 (wet) (**E**). Significant difference \* =  $p < 0.05$  compared with dry material, t-test (n = 16 for dry, n = 7 for  
347 wet). Data presented: mean (+/- standard error).

348 Figure 3. Dot-plot exhibiting the WCA of PET untreated control, cell culture media treated, UV treated  
349 and ethanol treated membranes. Media treated membrane exhibited a significantly different decrease  
350 in WCA ( $85.8^\circ \pm 20$ ) compared to control and all other treatments (**A**). One-way ANOVA followed  
351 by Tukey's post hoc test (n = 6). \* =  $p < 0.05$  significantly different to untreated control,  $\alpha = p < 0.05$   
352 significantly different to cell culture media treated,  $\varepsilon = p < 0.05$  significantly different to ethanol treated.  
353 Data presented: mean (+/- standard error). Photograph of WCA show the hydrophilic nature of the  
354 material (**B**).

355 Figure 4. FTIR spectra of electrospun membrane untreated control (**A**), tissue culture media treated  
356 (**B**), ethanol treated (**C**) and UV treated (**D**). All spectra exhibit the characteristic PET carbonyl peak  
357 at  $\sim 1700\text{cm}^{-1}$  with the media treated membrane exhibiting a peak at  $\sim 3400\text{cm}^{-1}$  suggesting evidence of  
358 protein interaction (n = 6).

359 Figure 5. Representative SEM micrographs and corresponding fluorescence images of  
360 DAPI/phalloidin stained ARPE-19 cells cultured on PET membranes for 1 month (**A**, **B**, **C**) and 3  
361 months (**D**, **E**, **F**). Cells populate the membrane with better coverage and more apparent phalloidin  
362 staining at 3 months culture. Microvilli (arrows) phenotypical of RPE cells are apparent by 1 month.  
363 (n = 3).

364 Figure 6. Representative immunofluorescent images show RPE cells cultured on the electrospun  
365 membrane for 1 month stained positively for RPE cell marker proteins and RPE function proteins  
366 (green). Cells cultured on the membranes were difficult to image clearly due to the auto-fluorescent  
367 nature of the PET fibres. Upon comparison with the positive glass coverslip control, similar staining  
368 patterns are apparent, especially noticeable with BEST1, GULP and USO1. DAPI = blue nuclear stain  
369 (n = 3).

370 Figure 7. The membrane does not allow invasion of cells through its architecture. H&E staining of  
371 cells cultured on the membrane for 1 week (**A**) up to 3 months (**B**) show the desired lack of cell  
372 invasion. The SEM micrograph (**C**) exhibits a lack of cells on the basal side of the membrane that had  
373 been seeded with ARPE-19 cells on its apical side and cultured for 3 months (n = 4).

374 Figure 8. Resazurin assay showed metabolism of cells cultured on the membranes was significantly  
375 lower in the initial 1 week of culture compared to glass coverslip controls. There was no significant  
376 difference in the metabolism of the cells thereafter up to 1 month. Significant difference  $*p<0.05$ , one-  
377 way ANOVA followed by Bonferroni post-test ( $n = 4$ ). Data presented: mean (+/- standard error).

378 Figure 9. Fluorescence barrier assays in the acellular substrate showed passive diffusion that plateaued  
379 FITC concentration across the membrane by 70 minutes (**A**), whereas fluorescence in the 1-month cell  
380 cultured membrane plateaued in the first 10 minutes of measurement suggesting the active transport of  
381 FITC by the monolayer of cells (**B**) ( $n = 4$ ). Data presented: mean (+/- standard error).

382 Figure 10. SEM micrographs show PLGA nanoparticles (**A, B**) were larger than PGA nanoparticles  
383 (**C, D**) Corresponding histograms showed PLGA averaged at 480nm (+/- 252) with a broader range of  
384 particle sizes, whereas PGA averaged at 59nm (+/-49) and exhibited less variation in particle size ( $n =$   
385 3). Data presented: mean (+/- standard error).

386 Figure 11. Representative images of live/dead staining (green/red) and corresponding SEM  
387 micrographs of ARPE-19 cells after 1 day's culture (**A-F**), 1 month's culture (**G-L**) on membrane only  
388 control, or with either PLGA or PGA nanoparticles decorated on the basal side of the membrane.  
389 Live/dead images show there is little difference between the three conditions with few dead cells  
390 present up to 1 month's culture. SEM micrographs show the progression in cells covering the  
391 membrane's apical surface ( $n = 3$ ).

392 Figure 12. Resazurin assay of ARPE-19 cells plated on membranes with PLGA or PGA nanoparticles  
393 decorated on the basal side showed significantly higher metabolism compared to membrane only  
394 controls for the first 14 days of culture. There was no significant difference in metabolism of the cells  
395 thereafter up to 1 month or compared with coverslip control. Significant difference  $*p<0.05$  compared  
396 with membrane control, one-way ANOVA followed by Bonferroni post-test ( $n = 4$ ). Data presented:  
397 mean (+/- standard error).

398 Figure 13. Effect of degrading nanoparticles on pH of ARPE-19 culture media exhibited little change,  
399 with PLGA exhibiting a significant decrease compared to membrane only control in week 1, which  
400 resolved thereafter. Significant difference  $*p<0.05$  compared to PET membrane only control, one-way  
401 ANOVA followed by Bonferroni post-test ( $n = 3$ ). Significant difference  $*p<0.05$  compared to PET  
402 membrane only control, one-way ANOVA followed by Bonferroni post-test ( $n = 6$ ). Data presented:  
403 mean (+/- standard error).

404 Figure 14. Release of FITC from PLGA and PGA nanoparticles into a solution of 0.1% isopropanol  
405 over a short period of time (**A, B**), long period of time (**C, D**) and the release of FITC into cell culture  
406 media (**E, F**) from nanoparticles electrosprayed onto the basal side of PET membrane. Significant  
407 difference  $*p<0.05$  compared to PET membrane only control, one-way ANOVA followed by  
408 Bonferroni post-test ( $n = 4$ ). Data presented: mean (+/- standard error).

409

410

411

412

413

414 **Tables**

415 Table 1. Primary antibody stains and the companies from where they were bought with corresponding  
416 catalogue numbers.

<b>Primary antibody</b>	<b>Company (catalogue number)</b>
Anti-Bestrophin/BEST1 antibody	Abcam (ab14927)
Anti-RPE65 antibody	Abcam (ab13826)
Anti-LRAT antibody	Abcam (ab166784)
Anti-PEDF antibody	Abcam (ab180711)
Anti-CRABP1 antibody	Abcam (ab235838)
Anti-MERTK antibody	Abcam (ab110108)
Anti-LAMP2 antibody [H4B4]	Abcam (ab25631)
Anti-USO1 antibody	Abcam (ab102470)
Anti-GULP antibody	Abcam (ab236893)
ZO-1	Thermofisher Scientific (61-7300)
Alexa Fluor 488 Phalloidin	Thermofisher Scientific (A12379)

417

418 **Conflict of Interest**

419 The authors declare that the research was conducted in the absence of any commercial or financial  
420 relationships that could be construed as a potential conflict of interest.

421 **Author Contributions**

422 RM performed the acquisition and undertook the analyses of the data and contributed to the writing of  
423 the manuscript. IP and SK provided critical evaluation on the progress of the work and guided the work  
424 through clinical relevance. SK also provided feedback on the manuscript. AH prepared, wrote and  
425 revised the manuscript, obtained the funding and is also leading the research.

426 **Funding**

427 EPSRC, Grant reference number: EP/S001468/1

428 **Abbreviations**

429 AMD: Aged related macular degeneration

430 RPE: Retinal pigment epithelium

431 PET: poly(ethylene terephthalate)

432 BM: Bruch's membrane

433 PLGA: poly(lactic acid-co-glycolic acid)

434 PGA: poly(glycolic acid)

435 VEGF: Vascular endothelial growth factor

436 FITC: Fluorescein-5-isothiocyanate

437 UV: Ultraviolet

438 DMEM: Dulbecco's modified eagles' media

439 SEM: Scanning electron microscope

440 DPBS: Dulbecco's phosphate buffered saline

441 DAPI: 4',6-diamidino-2-phenylindole

442 NBF: Neutral buffered formalin

443 UTS: Ultimate tensile strength

444 YM: Young's modulus

445 WCA: Water contact angle

446 FTIR: Fourier-transform infrared spectroscopy

447 Best1: Bestrophin 1

448 **Acknowledgements**

449 The authors would like to acknowledge Alison Beckett (University of Liverpool) for her help with the  
450 SEM to image the fibrous membrane and Dr Keith Arnold (Materials Innovations Factory, Liverpool)  
451 for his help with SEM in imaging the nanoparticles.

452

## 453 1 Data Availability Statement




454 The raw data supporting the conclusions of this manuscript will be made available by the authors,  
455 without undue reservation, to any qualified researcher.





## 456 References

- 457 Brandl, C., S. J. Zimmermann, V. M. Milenkovic, S. M. G. Rosendahl, F. Grassmann, A.  
458 Milenkovic, U. Hehr, M. Federlin, C. H. Wetzel, H. Helbig and B. H. F. Weber (2014). "In-Depth  
459 Characterisation of Retinal Pigment Epithelium (RPE) Cells Derived from Human Induced  
460 Pluripotent Stem Cells (hiPSC)." NeuroMolecular Medicine **16**(3): 551-564.
- 461 Chen, L., H.-H. Cheng, J. Xiong, Y.-T. Zhu, H.-P. Zhang, X. Xiong, Y.-M. Liu, J. Yu and Z.-X. Guo  
462 (2018). "Improved Mechanical Properties of Poly(butylene succinate) Membrane by Co-  
463 electrospinning with Gelatin." Chinese Journal of Polymer Science **36**(9): 1063-1069.
- 464 Curcio, C. A. and M. Johnson (2012). "Structure, Function, and Pathology of Bruch's Membrane."  
465 Retina Fifth Edition. **1**(465-481).
- 466 Curcio, C. A. and M. Johnson (2013). Chapter 20 - Structure, Function, and Pathology of Bruch's  
467 Membrane. Retina (Fifth Edition). S. J. Ryan, S. R. Sadda, D. R. Hinton et al. London, W.B.  
468 Saunders: 465-481.
- 469 da Cruz, L., K. Fynes, O. Georgiadis, J. Kerby, Y. H. Luo, A. Ahmado, A. Vernon, J. T. Daniels, B.  
470 Nommiste, S. M. Hasan, S. B. Gooljar, A.-J. F. Carr, A. Vugler, C. M. Ramsden, M. Bictash, M.  
471 Fenster, J. Steer, T. Harbinson, A. Wilbrey, A. Tufail, G. Feng, M. Whitlock, A. G. Robson, G. E.  
472 Holder, M. S. Sagoo, P. T. Loudon, P. Whiting and P. J. Coffey (2018). "Phase 1 clinical study of an  
473 embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration."  
474 Nature Biotechnology **36**(4): 328-337.
- 475 Del Priore, L. V., T. H. Tezel and H. J. Kaplan (2006). "Maculoplasty for age-related macular  
476 degeneration: Reengineering Bruch's membrane and the human macula." Progress in Retinal and Eye  
477 Research **25**(6): 539-562.
- 478 Haneef, A. S. and S. Downes (2015). "Assessing the Suitability of Electrospun Poly(Ethylene  
479 Terephthalate) and Polystyrene as Cell Carrier Substrates for Potential Subsequent Implantation as a  
480 Synthetic Bruch's Membrane." International Journal of Polymeric Materials and Polymeric  
481 Biomaterials **64**(6): 320-332.
- 482 Kawai, F., T. Kawabata and M. Oda (2019). "Current knowledge on enzymatic PET degradation and  
483 its possible application to waste stream management and other fields." Applied Microbiology and  
484 Biotechnology **103**(11): 4253-4268.
- 485 Kittredge, A., C. Ji, Y. Zhang and T. Yang (2018). "Differentiation, Maintenance, and Analysis of  
486 Human Retinal Pigment Epithelium Cells: A Disease-in-a-dish Model for BEST1 Mutations."  
487 Journal of visualized experiments : JoVE(138): 57791.
- 488 Kurokawa, N., S. Kimura and A. Hotta (2018). "Mechanical properties of poly(butylene succinate)  
489 composites with aligned cellulose-acetate nanofibers." Journal of Applied Polymer Science **135**(24):  
490 45429.
- 491 Liao, J.-L., J. Yu, K. Huang, J. Hu, T. Diemer, Z. Ma, T. Dvash, X.-J. Yang, G. H. Travis, D. S.  
492 Williams, D. Bok and G. Fan (2010). "Molecular signature of primary retinal pigment epithelium and  
493 stem-cell-derived RPE cells." Human Molecular Genetics **19**(21): 4229-4238.




- 494 Liu, Z., N. Yu, F. G. Holz, F. Yang and B. V. Stanzel (2014). "Enhancement of retinal pigment  
495 epithelial culture characteristics and subretinal space tolerance of scaffolds with 200 nm fiber  
496 topography." Biomaterials **35**(9): 2837-2850.
- 497 Lu, B., D. Zhu, D. Hinton, M. S. Humayun and Y.-C. Tai (2012). "Mesh-supported submicron  
498 parylene-C membranes for culturing retinal pigment epithelial cells." Biomedical Microdevices  
499 **14**(4): 659-667.
- 500 Moore, T. L., L. Rodriguez-Lorenzo, V. Hirsch, S. Balog, D. Urban, C. Jud, B. Rothen-Rutishauser,  
501 M. Lattuada and A. Petri-Fink (2015). "Nanoparticle colloidal stability in cell culture media and  
502 impact on cellular interactions." Chem Soc Rev **44**(17): 6287-6305.
- 503 Nowak, J. Z. (2006). "Age-related macular degeneration (AMD): pathogenesis and therapy."  
504 Pharmacol Rep **58**(3): 353-363.
- 505 Park, S.-Y., K.-B. Kang, N. Thapa, S.-Y. Kim, S.-J. Lee and I.-S. Kim (2008). "Requirement of  
506 Adaptor Protein GULP during Stabilin-2-mediated Cell Corpse Engulfment." Journal of Biological  
507 Chemistry **283**(16): 10593-10600.
- 508 Rudolf, M., C. A. Curcio, U. Schlötzer-Schrehardt, A. M. M. Sefat, A. Tura, Z. Aherrahrou, M.  
509 Brinkmann, S. Grisanti, Y. Miura and M. Ranjbar (2019). "Apolipoprotein A-I Mimetic Peptide L-4F  
510 Removes Bruch's Membrane Lipids in Aged Nonhuman Primates." Investigative Ophthalmology &  
511 Visual Science **60**(2): 461-472.
- 512 Sharma, N., P. Madan and S. Lin (2016). "Effect of process and formulation variables on the  
513 preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant  
514 study." Asian Journal of Pharmaceutical Sciences **11**(3): 404-416.
- 515 Sparrow, J. R., D. Hicks and C. P. Hamel (2010). "The retinal pigment epithelium in health and  
516 disease." Current molecular medicine **10**(9): 802-823.
- 517 Surrao, D. C., U. Greferath, Y. Q. Chau, S. J. Skabo, M. Huynh, K. J. Shelat, I. J. Limnios, E. L.  
518 Fletcher and Q. Liu (2017). "Design, development and characterization of synthetic Bruch's  
519 membranes." Acta Biomater **64**: 357-376.
- 520 Tan, E. Y. S., S. L. Sing and W. Y. Yeong (2019). 60 - Scaffolds for retinal repairs. Handbook of  
521 Tissue Engineering Scaffolds: Volume Two. M. Mozafari, F. Sefat and A. Atala, Woodhead  
522 Publishing: 673-691.
- 523 Thomson, H. A. J., A. J. Treharne, P. Walker, M. C. Grossel and A. J. Lotery (2011). "Optimisation  
524 of polymer scaffolds for retinal pigment epithelium (RPE) cell transplantation." British Journal of  
525 Ophthalmology **95**(4): 563.
- 526 White, C. E. and R. M. Olabisi (2017). "Scaffolds for retinal pigment epithelial cell transplantation in  
527 age-related macular degeneration." Journal of Tissue Engineering **8**: 2041731417720841.
- 528 Yamamoto, T. and H. Yamashita (1989). "Scanning electron microscopic observation of Bruch's  
529 membrane with the osmium tetroxide treatment." British Journal of Ophthalmology **73**: 162-167.

**A****B****C****D****E**





**A****B****C****D****E**

**A**









**B**





**A****Control****B****Media****UV****Ethanol****C****D**




**A****B****C****1 month****3 months****D****E****F**






**A**




**basal surface after 3 months' ARPE19  
culture on apical surface**




**B**

**C**


### Resazurin Assay







**A**



**B**





**A****PLGA****B****C****PGA****D**




**Control**

**PLGA**




**PGA**

**Row:  
A, B, C**

**1 day**






**Row:  
D, E, F**






**Row:  
G, H, I**


**1 month**




**Row:  
J, K, L**








### Resazurin Assay







**A****B****C****D****E****F**